NEMAR copy of ds007865
You're viewing the NEMAR copy at v1.0.0.
Each OpenNeuro pull is a NEMAR major bump
(vN.0.0); intermediate versions are NEMAR-side fixes.
Placebo Neuroepo multisession Phase II and III
A randomized, placebo-controlled clinical trial investigating the neuroprotective and neuromodulatory effects of intranasal NeuroEPO (erythropoietin) in Parkinson's disease patients. The study combines clinical assessments using the MDS-UPDRS III scale with EEG recordings at baseline and 9-month post-intervention timepoints to evaluate whether NeuroEPO-induced changes in brain function, as measured by EEG source activity, mediate cognitive and motor outcomes. This multisession Phase II/III dataset provides evidence for EPO's role in synaptic plasticity and dopaminergic system resilience.
AI-generated description, may include mistakesLoading demographics…
Coming soon. Per-file data-quality summaries are precomputed by the NEMAR processing pipeline. The static aggregate is on the way — tracked at nemar-cli#511.